The FDA has given Johnson & Johnson (NYS: JNJ) the green light to market Xarelto to prevent stroke among patients suffering from atrial fibrillation -- opening up a blockbuster market involving more than 2 million patients. Bayer, which holds ex-U.S. rights, has already estimated peak sales at close to $3 billion, and the treatment has the potential to work in the acute coronary syndrome area. J&J holds the U.S. rights to the drug.
"Atrial fibrillation can lead to the formation of blood clots, which can travel to the brain, blocking blood flow and causing a disabling stroke," said Dr. Norman Stockbridge, a director in the FDA's Center for Drug Evaluation and Research. "This approval gives doctors and patients another treatment option for a condition that must be managed carefully."
There are a couple of important catches to this approval, though. J&J did not get the right to boast that Xarelto is superior to warfarin, and the FDA added a black box warning against discontinuing the drug without talking it over with a physician.
Xarelto has already snagged an approval for preventing blood clots after orthopedic surgery, but that indication pales next to the $20 billion market that is emerging for therapies that can replace the problematic warfarin. Boehringer Ingelheim already won an approval for Pradaxa, giving it the first-to-market advantage. Pfizer (NYS: PFE) and Bristol-Myers Squibb (NYS: BMY) are not far behind with Eliquis.
At the time thisarticle was published The Motley Fool owns shares of Johnson & Johnson. Motley Fool newsletter services have recommended buying shares of Pfizer and Johnson & Johnson and creating a diagonal call position in Johnson & Johnson. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2011 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.